Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the various roles of RANK signaling in bone remodeling, immune function, and epithelial differentiation, highlighting its potential involvement in cancer mechanisms; it reports no new clinical results.

This study found that Flightless I (Flii) positively influences hair follicle regeneration in rodents, contrasting with its known negative effect on wound healing.

This study found that RANKL promotes the regeneration of type II alveolar epithelial cells in lung tissue, suggesting it may play a role in lung repair processes for diseases like COPD and fibrosis.

This study found that about 80% of known fullerene-binding proteins rank in the top 10% of scorers for C60 docking sites, confirming the accuracy of the predictive model used.

This study identified a novel G207E STING mutation causing a distinct phenotype involving alopecia, photosensitivity, and thyroid dysfunction, and suggests that common polymorphisms in TMEM173 and IFIH1 may influence disease presentation.

This study identified a novel G207E STING mutation associated with severe inflammatory symptoms and suggested that common polymorphisms in TMEM173 and IFIH1 may modify the phenotype in affected individuals.

This study highlights that alopecia areata, an autoimmune condition often starting in childhood, poses a higher risk of becoming chronic with an early onset and can result in poor therapy response.

This review suggests that oral Janus kinase inhibitors like tofacitinib, ruxolitinib, and baricitinib show promise for treating alopecia areata in adults, both in terms of efficacy and safety.

This study found that RANK-RANKL signaling regulates hair renewal and epidermal homeostasis in mice, revealing its role in initiating hair growth cycles and maintaining skin cell activity.

This article outlines the author's personal strategies for managing dermatological toxicities, such as acneiform rash and dry skin, associated with EGFR inhibitor therapy; it does not present new research findings.

This study observed that baricitinib treatment led to significant improvement in a patient's alopecia areata symptoms and suggests further clinical trials to explore its potential as a treatment.

This review discusses the development and selectivity of 5 alpha-reductase inhibitors, particularly non-steroidal ones, and reports no new clinical trial results.

This study found that chronic exposure to fadrozole or finasteride during frog development induced intersex individuals, which displayed different gene expression profiles depending on the chemical used.

This review discusses the potential uses of 5α-reductase inhibitors for conditions ranging from benign prostatic hyperplasia to skin disorders like acne and male pattern baldness, but it reports no new clinical results.

This source reports that a network meta-analysis found oral baricitinib and ruxolitinib to be effective and safe for treating alopecia areata, significantly improving response rates over placebos and showing fewer adverse effects than steroid treatments, though precise dosing needs further study.

This study compared JAK inhibitors for moderate-to-severe alopecia areata and found brepocitinib 30mg and deuruxolitinib 12mg to be most effective, though deuruxolitinib may cause more adverse events. Further research is needed for long-term efficacy and safety.

This study analyzed screening data from 218 alopecia areata patients before starting Janus kinase inhibitors, revealing the importance of pre-treatment screening due to risks of infections like tuberculosis and hepatitis B, with 74.8% of patients proceeding to treatment in real-world settings.

This study found that midazolam, unlike clonazepam, increased neurosteroid levels and affected synaptic inhibition and plasticity in rat hippocampal neurons, suggesting unique actions via dual receptor activation.

This study found that psychoemotional stress disrupts hair growth in mice by terminating anagen and suggests a potential pathway for pharmacological management of stress-related hair loss in humans.

This study found that finasteride significantly suppresses serum dihydrotestosterone levels at all tested doses in normal male volunteers without significant adverse effects.

This abstract discusses the unclear role of dihydrotestosterone (DHT) in postembryonic life in marsupials and possibly humans, reporting no new findings.

Finasteride effectively inhibits 5α reductase, while plant extracts like Permixon and Bazoton don't show significant results.

This study found that finasteride effectively reduced hirsutism in women during 12 months of treatment, with some effects persisting in the majority after stopping the medication.

This study found that 5α-reductase inhibitors significantly increase the risk of erectile dysfunction and hypoactive sexual desire in men with benign prostatic hyperplasia, compared to placebo.

This study reported no significant difference in efficacy or sexual dysfunction risk between 5α-reductase inhibitors and placebo for androgenetic alopecia, suggesting that dutasteride 0.5 mg may be considered pending further research.

The study observed that finasteride reduced fertility in male Sprague-Dawley rats by impairing the formation of copulatory plugs, an effect considered specific to rats and not applicable to species without this reproductive feature.

High doses of finasteride cause cell growth and tumors in mice.

This study found that 4-MA is a potent inhibitor of testosterone 5α-reductase in human tissues, promising potential for treating androgen-dependent skin conditions like male pattern baldness.

This article reviews the effects of 5 alpha-reductase inhibitors for treating conditions like male pattern baldness and benign prostatic hyperplasia, noting significant DHT reduction but reports no new clinical results.

This study found that long-term use of 5α-reductase inhibitors is associated with improved overall survival in men with renal cell carcinoma, particularly those with low comorbidity not receiving surgery or systemic therapy, suggesting a potential role for androgen modulation in disease management.